title: Prognostic impact of p300 expression in patients with colorectal cancer.
abstract: BACKGROUND
  This study evaluated the expression of p300 in colorectal cancer, its relationship with clinicopathological characteristics, and its potential prognostic significance.
  
  
  METHODS
  The expression of p300 was measured using immunohistochemistry in tumors and surrounding normal mucosa from 199 patients with primary colorectal cancer. The patients were followed for a median period of 83 months.
  
  
  RESULTS
  Nuclear p300 expression was significantly associated with histology (P = 0.031) and lymph node involvement (P = 0.019). When the low and high p300 groups were subdivided according to tumor location, the disease-free survival rate differed only for the patients with colon cancer (P = 0.008). In addition, the disease-free survival significantly differed with p300 expression for stage II disease (P = 0.038), but not for stage III disease. Multivariate analysis revealed that lymph node involvement (P = 0.014) and p300 expression (P = 0.032) were independent predictors of overall survival in adenocarcinomas.
  
  
  CONCLUSIONS
  The overexpression of p300 may be an independent favorable prognostic factor for disease-free survival in patients with colorectal cancer.
authors.affiliation: Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Jung Wook
authors.initials: JW
authors.lastname: Huh
authors.forename: Hee Cheol
authors.initials: HC
authors.lastname: Kim
authors.forename: Seok Hyung
authors.initials: SH
authors.lastname: Kim
authors.forename: Yoon Ah
authors.initials: YA
authors.lastname: Park
authors.forename: Yong Beom
authors.initials: YB
authors.lastname: Cho
authors.forename: Seong Hyeon
authors.initials: SH
authors.lastname: Yun
authors.forename: Woo Yong
authors.initials: WY
authors.lastname: Lee
authors.forename: Ho-Kyung
authors.initials: HK
authors.lastname: Chun
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry* / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D015179:Colorectal Neoplasms / Q000737:chemistry* / Q000473:pathology; D018572:Disease-Free Survival; D050881:E1A-Associated p300 Protein / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D012107:Research Design; D015854:Up-Regulation
chemical_list: D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D050881:E1A-Associated p300 Protein; C494360:EP300 protein, human
keywords: colorectal cancer; immunohistochemistry; p300